Alzheimer's Drug Works in Dementia Due to Parkinson's: FDA panel weighs in on new indication.

GAITHERSBURG, MD. — The cholinesterase inhibitor rivastigmine is likely to be approved for a second indication: the treatment of mild to moderate dementia associated with Parkinson's disease, based on a study that found treatment was associated with significant benefits in cognition, behavior, and activities of daily living in such patients.